- Home
- SB vs ALEC Comparison
SB vs ALEC Comparison
Compare SB & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- ALEC
- Stock Information
- Founded
- SB 2007
- ALEC 2013
- Country
- SB Monaco
- ALEC United States
- Employees
- SB N/A
- ALEC N/A
- Industry
- SB Marine Transportation
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SB Consumer Discretionary
- ALEC Health Care
- Exchange
- SB Nasdaq
- ALEC Nasdaq
- Market Cap
- SB 454.8M
- ALEC 454.5M
- IPO Year
- SB 2008
- ALEC 2019
- Fundamental
- Price
- SB $4.26
- ALEC $4.07
- Analyst Decision
- SB
- ALEC Strong Buy
- Analyst Count
- SB 0
- ALEC 6
- Target Price
- SB N/A
- ALEC $17.75
- AVG Volume (30 Days)
- SB 531.7K
- ALEC 653.8K
- Earning Date
- SB 11-13-2024
- ALEC 11-06-2024
- Dividend Yield
- SB 4.68%
- ALEC N/A
- EPS Growth
- SB 35.10
- ALEC N/A
- EPS
- SB 0.90
- ALEC N/A
- Revenue
- SB $318,430,000.00
- ALEC $61,508,000.00
- Revenue This Year
- SB $9.46
- ALEC N/A
- Revenue Next Year
- SB N/A
- ALEC $118.87
- P/E Ratio
- SB $4.76
- ALEC N/A
- Revenue Growth
- SB 10.27
- ALEC N/A
- 52 Week Low
- SB $3.45
- ALEC $3.94
- 52 Week High
- SB $6.33
- ALEC $8.90
- Technical
- Relative Strength Index (RSI)
- SB 40.09
- ALEC 35.93
- Support Level
- SB $4.31
- ALEC $4.82
- Resistance Level
- SB $4.44
- ALEC $6.14
- Average True Range (ATR)
- SB 0.10
- ALEC 0.45
- MACD
- SB 0.03
- ALEC -0.08
- Stochastic Oscillator
- SB 44.12
- ALEC 1.19
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.